ERBB2 and breast cancer: Trastuzumab-conjugated PROTAC-loaded nanoparticles (MZ1-loaded polymeric antibody-conjugated nanoparticles) have also demonstrated enhanced specificity and cytotoxicity in HER-2 enriched BC (425).